FDA Approves AOP Health’s Rapiblyk™ (Landiolol) for Atrial Fibrillation and Flutter in Critical Care

AOP Orphan Pharmaceuticals GmbH (AOP Health), based in Vienna, Austria, has announced that the U.S. Food and Drug Administration (FDA) has approved Rapiblyk™ (landiolol) for the treatment of supraventricular tachycardia (SVT), including atrial fibrillation and atrial flutter, in critical care…

Read MoreFDA Approves AOP Health’s Rapiblyk™ (Landiolol) for Atrial Fibrillation and Flutter in Critical Care

Galderma’s Phase III OLYMPIA 1 Data Shows Nemolizumab Improves Prurigo Nodularis Symptoms

Galderma recently announced that the full results from the Phase III OLYMPIA 1 trial, which evaluated the efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis, were published in JAMA Dermatology. The data from this trial, in conjunction…

Read MoreGalderma’s Phase III OLYMPIA 1 Data Shows Nemolizumab Improves Prurigo Nodularis Symptoms

QIAGEN Expands QIAstat-Dx with New Barcelona Site to Boost Infectious Disease and Precision Medicine Growth

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today revealed plans to relocate its QIAstat-Dx operations to a new facility in Esplugues de Llobregat, near Barcelona. This move is part of a multi-year investment aimed at expanding and strengthening the company’s…

Read MoreQIAGEN Expands QIAstat-Dx with New Barcelona Site to Boost Infectious Disease and Precision Medicine Growth

EU Approves BeiGene’s TEVIMBRA for Advanced Esophageal and Gastric Cancers

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company set to rebrand as BeOne Medicines, today announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination with chemotherapy for the first-line treatment of esophageal squamous cell…

Read MoreEU Approves BeiGene’s TEVIMBRA for Advanced Esophageal and Gastric Cancers

Aulos Bioscience Doses First Patient in Phase 2 Trial of Avelumab and AU-007 for NSCLC

Aulos Bioscience, an innovative immuno-oncology company focused on developing potentially groundbreaking IL-2 therapeutics to revolutionize cancer care, has announced the dosing of its first patient in a Phase 2 clinical trial. The trial evaluates the combination of AU-007, avelumab (a…

Read MoreAulos Bioscience Doses First Patient in Phase 2 Trial of Avelumab and AU-007 for NSCLC